3 ms·

You seem to be ignoring the fact that preclinical trials are experiencing abysmal replication rates in studies geared towards that end. There's ongoing work on

You seem to be ignoring the fact that preclinical trials are experiencing abysmal replication rates in studies geared towards that end. There's ongoing work on replication of clinical studies, but I would hypothesize that we are going to see the same problem there. The point here being that the systems in place do not seem be working as an effective system of checks and balances, and so bias in part of the individuals and organizations involved is rather important.

Gatsky 8y ago
No, Baselga is primarily a clinical trialist, so it isn’t relevant to this discussion. Clinical trials have standardised designs and procedures, the number of experimental subjects is large (compared to preclinical lab experiments), and orthogonal outcome measures are collected to enhance validity (like response rate and survival outcomes). Most doctors are trained and experienced in interpreting clinical trials, and are well aware of the limitations, which are constantly highlighted in conference discussions and the literature. Finally, clinical trials are replicated all the time (surprised you would suggest otherwise?). A drug is tested in phase 1, phase 2 and phase 3 trials of increasing size, and drugs from the same class are also tested in competing trials.